Evidence map›Paper›PMID 40195407›Full record

ArticleScientific reports2025

Antiviral effect of Bromelain combined with acetylcysteine against SARS-CoV-2 Omicron variant.

Erik Vinicius de Sousa Reis, Linziane Lopes Ferreira, Felipe Alves Clarindo, Geovane Marques-Ferreira, Leonardo Camilo de Oliveira, Thaís de Fátima Silva Moraes, Luciana Debortoli de Carvalho, Flávio Guimarães da Fonseca, Adriano de Paula Sabino, Mathew Suji Eapen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. SARS-CoV-2 drives upregulation of EpCAM in respiratory epithelial cells with hypercellular profile during severe COVID-19.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Erik Vinicius de Sousa ReisLaboratório de Virologia Básica e Aplicada (LVBA), Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Linziane Lopes FerreiraLaboratório de Virologia Básica e Aplicada (LVBA), Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Felipe Alves ClarindoLaboratório de Virologia Básica e Aplicada (LVBA), Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Geovane Marques-FerreiraLaboratório de Virologia Básica e Aplicada (LVBA), Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Leonardo Camilo de OliveiraCT Terapias Avançadas e Inovadoras, (CT-Terapias), Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Thaís de Fátima Silva MoraesLaboratório de Virologia Básica e Aplicada (LVBA), Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Luciana Debortoli de CarvalhoLaboratório de Microbiologia, Departamento de ciências biológicas, universidade estadual de Santa Cruz, Ilhéus, Bahia, Brazil.
Flávio Guimarães da FonsecaLaboratório de Virologia Básica e Aplicada (LVBA), Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Adriano de Paula SabinoLaboratório de Hematologia Clínica, Experimental e Molecular, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia/UFMG, Belo Horizonte, Brazil.
Mathew Suji EapenLaboratório de Virologia Básica e Aplicada (LVBA), Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Mauro Martins TeixeiraCT Terapias Avançadas e Inovadoras, (CT-Terapias), Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Sarah J ValleMucpharm, Sydney, Australia. sarah@mucpharm.com.
David L MorrisMucpharm, Sydney, Australia. david.morris@unsw.edu.au.
Jordana Grazziela Alves Coelho-Dos-ReisLaboratório de Virologia Básica e Aplicada (LVBA), Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. reisjordana@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent pandemic represented one of the biggest challenges of modern civilization. SARS-CoV-2 remains an imminent public health threat and currently, there is no effective and greatly affordable treatment for severe COVID-19. Although standard management with dexamethasone, and physical management including physiotherapy, prone positioning and mechanical ventilation are used, severe disease patients may still succumb to infection. In this regard, BromAc

Indexed as

AcetylcysteineAntiviral AgentsBromelainsCOVID-19 Drug TreatmentSARS-CoV-2AnimalsChlorocebus aethiopsCOVID-19HumansSpike Glycoprotein, CoronavirusVero CellsAcetylcysteineAntiviral AgentsBromelainsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2BromAc®COVID-19MucolyticSARS-CoV-2

Identifiers

PMID40195407
PMCPMC11976912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.